Emerging Topical and Systemic JAK Inhibitors in Dermatology

December 2019 in “ Frontiers in Immunology ”

Farzan Solimani, Katharina Meier, Kamran Ghoreschi

Janus kinase inhibitors JAK inhibitors alopecia areata atopic dermatitis psoriasis cytokines systemic administration topical administration JAKi

TLDR JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

The document reviewed the emerging role of Janus kinase inhibitors (JAKi) in dermatology, focusing on their potential for treating conditions like alopecia areata (AA), atopic dermatitis (AD), psoriasis vulgaris (PSO), and vitiligo. JAKi, such as tofacitinib and baricitinib, showed promise in modulating cytokine signaling pathways, leading to hair regrowth in AA and symptom improvement in AD and PSO. However, effects were often temporary and reversed upon discontinuation. In vitiligo, JAKi aided repigmentation, especially with phototherapy. Challenges included developing selective JAKi to minimize toxicity risks, such as anemia and elevated cholesterol. While newer JAKi showed improved selectivity, concerns about infections and long-term risks persisted. Economically, JAKi were favorable, but further research was needed to confirm their efficacy and safety compared to traditional treatments.

View this study on frontiersin.org →

Discuss this study in the Community →

Research cited in this study

21 / 21 results

research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

88 citations , August 2019 in “Frontiers in immunology”

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

research Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata

32 citations , April 2019 in “JAAD case reports”

JAK inhibitors helped treat hair loss in two people with Down syndrome.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

research JAK Inhibitors and Alopecia Areata

56 citations , January 2019 in “Lancet”

JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

66 citations , December 2018 in “Dermatology”

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata

11 citations , December 2018 in “Journal of the European Academy of Dermatology and Venereology”

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

research Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes

24 citations , October 2018 in “JAAD Case Reports”

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series

79 citations , September 2018 in “Dermatologic therapy”

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

research Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor

16 citations , June 2018 in “JAAD case reports”

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology

63 citations , April 2018 in “Journal of the American Academy of Dermatology”

Topical JAK inhibitors may help treat some skin conditions but need more research.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , February 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

Topical JAK inhibitors may help children with alopecia areata regrow hair.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , November 2016 in “Journal of the American Academy of Dermatology”

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Drug Delivery with Topically Applied Nanoparticles: Science Fiction or Reality?

39 citations , January 2013 in “Skin pharmacology and physiology”

Nanoparticles show promise for drug delivery through hair follicles but not through healthy skin.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

421 citations , April 2012 in “The New England Journal of Medicine”

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

research Graft-Versus-Host Disease: Comprehensive Overview by the American Academy of Dermatology

58 citations , April 2012 in “Journal of the American Academy of Dermatology”

Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.

research Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity

717 citations , June 2010 in “Nature”

Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.

Related Research

9 / 9 results

$Refractory Alopecia Universalis Associated with Dermatomyositis Successfully Treated with Tofacitinib$

research Comorbidities in Dermatology

9 citations , November 2018 in “Dermatologic Clinics”

Understanding related health issues in skin disease patients is crucial for better care.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.